These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 26373560)

  • 21. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides.
    Terrier B; Saadoun D; Sène D; Ghillani P; Amoura Z; Deray G; Fautrel B; Piette JC; Cacoub P
    Ann Rheum Dis; 2009 Oct; 68(10):1564-71. PubMed ID: 18957481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis.
    Yoo J; Kim HJ; Jung SM; Song JJ; Park YB; Lee SW
    Int J Rheum Dis; 2017 Oct; 20(10):1593-1605. PubMed ID: 28766857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An index for renal outcome in ANCA-associated glomerulonephritis.
    Vergunst CE; van Gurp E; Hagen EC; van Houwelingen HC; Hauer HA; Noël LH; Waldherr R; Ferrario F; van der Woude FJ; Bruijn JA; Bajema IM;
    Am J Kidney Dis; 2003 Mar; 41(3):532-8. PubMed ID: 12612975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.
    Rhee RL; Davis JC; Ding L; Fervenza FC; Hoffman GS; Kallenberg CGM; Langford CA; McCune WJ; Monach PA; Seo P; Spiera R; St Clair EW; Specks U; Stone JH; Merkel PA
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):251-257. PubMed ID: 29371340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns.
    Oristrell J; Loureiro-Amigo J; Solans R; Valenzuela MP; Monsálvez V; Segarra A; Amengual MJ; Marín A; Feijoo C; Tolosa C
    Clin Exp Immunol; 2021 Feb; 203(2):209-218. PubMed ID: 33020895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High anti-neutrophil cytoplasmic antibody titers are associated with the requirement of permanent dialysis in patients with myeloperoxidase-ANCA-associated vasculitis.
    Yen CL; Tian YC; Wu HH; Tu KH; Liu SH; Lee CC; Fang JT; Yang CW; Li YJ
    J Formos Med Assoc; 2019 Oct; 118(10):1408-1415. PubMed ID: 31133523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement.
    Casal Moura M; Specks U; Tehranian S; Sethi S; Zubidat D; Nardelli L; Dos Santos FG; Sousa C; León-Róman J; Bobart SA; Greene E; Zand L; Fervenza FC
    Clin J Am Soc Nephrol; 2023 Jan; 18(1):47-59. PubMed ID: 36526414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chest and renal involvements, Birmingham vascular activity score more than 13.5 and five factor score (1996) more than 1 at diagnosis are significant predictors of relapse of microscopic polyangiitis.
    Oh YJ; Ahn SS; Park ES; Jung SM; Song JJ; Park YB; Lee SW
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):47-54. PubMed ID: 28134074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoking Is a Risk Factor for Relapse of Antimyeloperoxidase Antibodies-Associated Vasculitis.
    Yamaguchi M; Ando M; Katsuno T; Tsuboi N; Maruyama S
    J Clin Rheumatol; 2018 Oct; 24(7):361-367. PubMed ID: 29667942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).
    Durel CA; Berthiller J; Caboni S; Jayne D; Ninet J; Hot A
    Arthritis Care Res (Hoboken); 2016 Mar; 68(3):374-87. PubMed ID: 26315340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis.
    Yoshida M; Sasaki M; Nakabayashi I; Akashi M; Tomiyasu T; Yoshikawa N; Kojima T; Ohno N; Yamada M
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S28-32. PubMed ID: 19646343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome and treatment of elderly patients with ANCA-associated vasculitis.
    Weiner M; Goh SM; Mohammad AJ; Hruskova Z; Tanna A; Bruchfeld A; Selga D; Chocova Z; Westman K; Eriksson P; Pusey CD; Tesar V; Salama AD; Segelmark M
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1128-35. PubMed ID: 26100457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A preliminary study of the significance of autoantibodies against light chain of myeloperoxidase on pulmonary damages in myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
    Zhang L; Shuai Z; Hu Z; Zhang M; Chen S
    Zhonghua Nei Ke Za Zhi; 2015 Jun; 54(6):511-6. PubMed ID: 26359012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-neutrophil cytoplasmic antibody-associated vasculitis. Clinical aspects and treatment].
    Paolini MV; Ruffino JP; Fernández Romero DS
    Medicina (B Aires); 2013; 73(2):119-26. PubMed ID: 23570759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cyclophosphamide on the prognosis of Japanese patients with renal vasculitis associated with anti-neutrophil cytoplasmic antibody-positive microscopic polyangiitis.
    Iwabuchi M; Nakaya I; Tsuchiya Y; Shibagaki Y; Yamaguchi T; Fukuhara S; Oe Y; Sakuma T; Sato T; Taguma Y; Soma J
    Clin Exp Nephrol; 2016 Oct; 20(5):712-719. PubMed ID: 26590052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis.
    Menez S; Hruskova Z; Scott J; Cormican S; Chen M; Salama AD; Alasfar S; Little MA; Safrankova H; Honsova E; Tesar V; Geetha D
    Am J Nephrol; 2018; 48(6):465-471. PubMed ID: 30472700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.